Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder

Journal of the National Cancer Institute

Volumn 96, Issue 19, 2004, Pages 1447-1457

  Roychowdhury, Sameek ^a   Baiocchi, Robert A ^a   Vourganti, Srinivas ^a   Bhatt, Darshna ^a   Blaser, Bradley W ^a   Freud, Aharon G ^a   Chou, Jason ^a   Chen, Chang Shi ^a   Xiao, Jim J ^a,b   Parthun, Mark ^a   Chan, Kenneth K ^a,b   Eisenbeis, Charles F ^a,b   Ferketich, Amy K ^a   Grever, Michael R ^a   Chen, Ching Shih ^a,b   Caligiuri, Michael A ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CASPASE 3; CASPASE INHIBITOR; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; CASPASE; CYCLOPEPTIDE; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; ENZYME INHIBITOR; FR 901228; HISTONE DEACETYLASE; MATRIX PROTEIN; PROTEIN BCL 2; THYMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CELL SYNCHRONIZATION; CELL VIABILITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; XENOGRAFT; ANIMAL; CELL DIVISION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNE DEFICIENCY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOBLASTOMA; METABOLISM; TUMOR CELL LINE; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CASPASES; CELL DIVISION; CELL LINE, TUMOR; DEPSIPEPTIDES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASES; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, LYMPHOBLASTIC; MICE; NF-KAPPA B; PEPTIDES, CYCLIC; PROTO-ONCOGENE PROTEINS C-BCL-2; THYMIDINE; TRANSPLANTATION, HETEROLOGOUS; VIRAL MATRIX PROTEINS;

EID: 6944240526     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh271     Document Type: Article

References (50)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, editor. Fields' virology. Vol 1. 4th ed. New York (NY): Lippincott Williams & Wilkins; 2001. p. 2575-627.
2. Kieff E, Rickinson AB. Epstein-Barr virus and replication. In Fields BN, editor. Fields' virology. Vol 1. 4th ed. New York (NY): Lippincott Williams & Wilkins; 2001. p. 2511-73.
3. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
4. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
5. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8.
6. Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1994;91:5577-81.
7. Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med 1993;178:1103-7.
8. Li Z, Chan KK. A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. J Pharm Biomed Anal 2000;22:33-44.
9. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
10. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-51.
11. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 1995;85:1063-74.
12. Robertson MJ, Manley TJ, Pichert G., Cameron C, Cochran KJ, Levine H, et al. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 1995;17:51-61.
13. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
14. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000;192:571-80.
15. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94:1745-57.
16. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102:652-8.
17. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
18. Klein JP, Moeschberger, ML. Survival analysis: techniques for censored and truncated data. New York (NY): Springer; 1997.
19. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991;349:612-4.
20. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
21. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996;16:7098-108.
22. Chang L, Liu ST. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res 2000;28: 3918-25.
23. Jenkins PJ, Binne UK, Farrell PJ. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 2000;74:710-20.
24. Radkov S, Touitou R, Brehm A, Rowe M, West M, Kourzarides R, et al. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 1999;73:5688-97.
25. Wang L, Grossman SR, Kieff E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A 2000;97: 430-5.
26. Sjoblom-Hallen A, Yang W, Jansson A, Rymo L. Silencing of the Epstein-Barr virus latent membrane protein 1 gene by the Max-Mad1-mSin3A modulator of chromatin structure. J Virol 1999;73:2983-93.
27. Wu DY, Kalpana GV, Goff SP, Schubach WH. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol 1996;70:6020-8.
28. Knight JS, Lan K, Subramanian C, Robertson ES. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B cell lines. J Virol 2003; 77:4261-72.
29. Corcoran EE, Means AR. Defining Ca(2+)/calmodulin-dependent protein kinase cascades in transcriptional regulation. J Biol Chem 2002; 276:2975-8.
30. Blaeser F, Ho N, Prywes R, Chatila TA. Ca(2 +)-dependent gene expression mediated by MEF2 transcription factors. J Biol Chem 2000; 275:197-209.
31. Baiocchi RA, Sekula T, Vourganti S, Nair V, Roychowdhury S, Parthun M, et al. Treatment of EBV-transformed B cell lines with depsipeptide results in the induction of a viral thymidine kinase and enhanced susceptibility to antiviral-induced apoptosis. Proceedings of the EORTC, NCI, and American Association for Cancer Research; 2001 Nov 2; Miami, FL.
32. Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, et al. mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 2003;23:7475-87.
33. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
34. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 2003;63:8948-54.
35. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-11.
36. Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, et al. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 1997;57:2508-15.
37. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
38. Park JH, Faller DV. Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology 2002;303:345-63.
39. Mosialos G. Cytokine signaling and Epstein-Barr virus-mediated cell transformation. Cytokine Growth Factor Rev 2001;12:259-70.
40. Kenney JL, Guinness ME, Reiss M, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int J Cancer 2001;91:89-98.
41. Alazard N, Gruffat H, Hiriart E, Sergeant A, Manet E. Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin. J Virol 2003;77:8166-72.
42. Knight JS, Lan K, Subramanian C, Robertson ES. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 2003; 77:4261-72.
43. Sjoblom-Hallen A, Yang W, Jansson A, Rymo L. Silencing of the Epstein-Barr virus latent membrane protein-1 gene by the Max-Mad-mSin3A modulator of chromatin structure. J Virol 1999;73:2983-93.
44. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53 mediated apoptosis through the induction of the A20 gene. J Virol 1996;70:8653-9.
45. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
46. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 1999;18:6959-64.
47. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 2000;97: 6055-60.
48. Catz SD, Johnson JL. Transcriptional regulation of bcl-2by nuclear factor kB and its significance in prostate cancer. Oncogene 2001;20:7342-51.
49. Wang CY, Guttridge DC, Mayo M, Baldwin AS. NF-kappaB induces expression of the Bcl2 homologue A1/BfL-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
50. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987;23:1283-7.